Antennova to Present Latest Data of ATN-037 in a Mini Oral Presentation at ESMO Congress 2024
BOSTON, Sept. 8, 2024 /PRNewswire/ — Antennova, a clinical-stage biotech company focused on oncology today announced that it will present the…
Brand Post
ESMO 2024 | Ascentage Pharma to Present Updated Data of Olverembatinib in Patients with SDH-Deficient GIST during a Mini Oral Presentation at the 2024 ESMO Congress
ROCKVILLE, Md. and SUZHOU, China, Sept. 8, 2024 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing…
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13)…
Eisai to Present E7386, co-created by PRISM BioLab and Eisai, at the ESMO (European Society for Medical Oncology) Annual Meeting
Abstract Released for E7386, Created Through Collaborative Research Between Eisai and PRISM TOKYO, Sept. 8, 2024 /PRNewswire/ — PRISM BioLab, Co.…
Toshiba Unveils the High-End Masterstroke Series at IFA 2024, Showcasing a New Era of Masterpiece Appliances
BERLIN, Sept. 8, 2024 /PRNewswire/ — Toshiba, a brand renowned for its over a century of excellence in craftsmanship and…
Saudi Arabia’s landmark Global AI Summit to address harnessing AI for the good of humanity
RIYADH, Saudi Arabia, Sept. 8, 2024 /PRNewswire/ — Ahead of the Global AI Summit (GAIN) this week, H.E. Dr. Abdullah bin…
MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024
MacroGenics to host investor call to review key data presented at ESMO on Monday, September 16, 2024, at 8:00 a.m.…
ALIMENTATION COUCHE-TARD COMMENTS ON SEVEN & I HOLDINGS’ RESPONSE NOT TO ENGAGE IN FRIENDLY DISCUSSIONS REGARDING A VALUE CREATING COMBINATION
LAVAL, QC, Sept. 8, 2024 /PRNewswire/ – Alimentation Couche-Tard Inc. (“Couche-Tard” or the “Corporation”) (TSX: ATD), a global leader in…
Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress
8 September 2024 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Avacta to present updated clinical data on…
Resecurity Partners with Mannai Trading Corporation to Bolster Cybersecurity in Qatar
LOS ANGELES, Sept. 8, 2024 /PRNewswire/ — Resecurity, a global leader in cybersecurity solutions protecting Fortune 100 corporations and government agencies…
SPEE3D SHOWCASES EXPEDITIONARY MANUFACTURING UNIT (EMU) FOR THE FIRST TIME IN AUSTRALIA AT LAND FORCES INTERNATIONAL EXPOSITION
Australian Defence Purchases SPEE3DCell Post-Processing Additive Manufacturing Units for Ongoing Support of the Ukraine War to Complement Existing WarpSPEE3D Printers…
RYBREVANT®▼ (amivantamab) plus lazertinib show strong favourable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
New longer-term data from the MARIPOSA study confirm superior outcomes of amivantamab plus lazertinib regimen compared to osimertinib monotherapy as…
ICEYE to deliver SAR satellites and data to Greece’s National Satellite Space Project in collaboration with the European Space Agency
SAR satellites and data enable Greece to monitor their areas of interest and improve their natural catastrophe detection and maritime…
Perioperative Ivonescimab (PD-1/VEGF) for NSCLC Demonstrated Clinically Significant Phase II Results, Presented in Oral Session at WCLC 2024
HONG KONG, Sept. 8, 2024 /PRNewswire/ — Akeso (9926. HK) announced that its internally developed PD-1/VEGF bispecific antibody ivonescimab showed…
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
New longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANT® plus LAZCLUZE™ regimen compared to osimertinib monotherapy…
↑